Respiratory tract

Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Friday, November 3, 2023

LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTCQB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023.

Key Points: 
  • OTCQB companies must be current in their financial reporting and undergo an annual verification and management certification process.
  • We remain optimistic of successful outcomes from these efforts in the coming months,” commented Vu Truong, Ph.D., Chief Executive Officer of Aridis Pharmaceuticals.
  • Due to fair value option valuation of our notes payable, there was no interest expense recorded during the third quarter of 2023.
  • Other Income: Other income increased to $26,000 for the quarter ended September 30, 2023, compared to approximately $23,000 for the quarter ended September 30, 2022.

Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients

Retrieved on: 
Monday, March 13, 2023

LOS GATOS, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced preliminary top-line results from the randomized, double blinded, placebo-controlled Phase 2a study of AR-501, which evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as an inhaled aerosol in cystic fibrosis (CF) patients with confirmed Pseudomonas aeruginosa bacterial and other potential infections. The study was conducted with funding support from the Cystic Fibrosis Foundation. AR-501 is being developed as a once-per-week inhaled dosing regimen that is self-administered using a commercially available nebulizer device.

Key Points: 
  • The study was conducted with funding support from the Cystic Fibrosis Foundation.
  • AR-501 is being developed as a once-per-week inhaled dosing regimen that is self-administered using a commercially available nebulizer device.
  • Three weekly inhaled doses of AR-501 at 6.4mg, 20mg, and 40mg dose levels were well tolerated in CF patients.
  • “Having met the primary and secondary endpoints of this study, we thank the Cystic Fibrosis Foundation for the tremendous support they’ve provided to help us complete this study” said Aridis’ CEO Vu Truong, PhD.

Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®

Retrieved on: 
Wednesday, February 8, 2023

ALLSCHWIL, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company has executed term sheets describing a clinical trial partnership with SPRIM Global Investments (SGI), a leading health sciences venture capital firm with deep industry expertise and decades of operating experience across 17 countries. The partnership, which includes a debt facility, is expected to provide Spexis with up to half of the Phase 3 clinical development costs of ColiFin® and enable the initiation of Spexis’ Phase 3 COPILOT study, expected in the second quarter of 2023. COPILOT will evaluate and confirm the use of once versus twice daily dosing for COPA, the planned single pivotal efficacy and safety Phase 3 trial. While the majority of such funding is planned to be in the form of senior debt tied to the funding of the COPILOT and COPA studies, SGI has also invested in Spexis via an interest-bearing subordinated convertible note financing in an amount of $500,000, with a term of 2 years and partial warrant coverage. Spexis expects to secure additional investors in the near future.

Key Points: 
  • The partnership, which includes a debt facility, is expected to provide Spexis with up to half of the Phase 3 clinical development costs of ColiFin® and enable the initiation of Spexis’ Phase 3 COPILOT study, expected in the second quarter of 2023.
  • COPILOT will evaluate and confirm the use of once versus twice daily dosing for COPA, the planned single pivotal efficacy and safety Phase 3 trial.
  • “This collaboration is expected to provide capitalization through significant clinical milestones in ColiFin®’s Phase 3 development.
  • Spexis has worldwide rights to ColiFin® ex-Europe and is focused on developing the product first for the U.S. market.

Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection

Retrieved on: 
Thursday, January 19, 2023

BARCELONA, Spain, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Pulmobiotics SL, a biotechnology company pioneering novel live biotherapeutics for the treatment of lung diseases, and the Centre for Genomic Regulation (CRG), an international biomedical research institute of excellence whose mission is to discover and advance knowledge for the benefit of society, public health and economic prosperity, today announced the publication of preclinical results demonstrating that treatment using Pulmobiotics’ engineered live biotherapeutic significantly reduced antibiotic-resistant Pseudomonas aeruginosa infections in the lungs of mice, thereby improving survival rates, and dissolved biofilms formed on endotracheal tubes of patients with ventilator-associated pneumonia (VAP). These data highlight a promising new approach to treat antibiotic-resistant Pseudomonas aeruginosa lung infections, a leading cause of mortality in hospital settings, and could offer a potential alternative to the use of antibiotics that enable antibiotic resistance, a global public health crisis. Importantly, these data also support the application of Pulmobiotics’ synthetic biology research platform to discover and develop novel live biotherapeutics for the treatment of other serious lung diseases.

Key Points: 
  • Importantly, these data also support the application of Pulmobiotics’ synthetic biology research platform to discover and develop novel live biotherapeutics for the treatment of other serious lung diseases.
  • This publication is the first time data has been described for a live biotherapeutic for the treatment of lung infection caused by Pseudomonas aeruginosa.
  • The results are published in Nature Biotechnology and this research is supported by the European Research Council through an H2020 project and “la Caixa” Foundation through the CaixaResearch Health Call.
  • Treatment led to a significant reduction in Pseudomonas aeruginosa bacterial load with the Pulmobiotics treatment alone or in combination with ceftolozane/taxobactam antibiotics.

Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities

Retrieved on: 
Monday, January 9, 2023

CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today provided an update on recent advancements of its Prime Editing technology and progress across its initial pipeline of eighteen programs, and outlined its strategic priorities and expected milestones for 2023.

Key Points: 
  • Today, Prime Medicine announced new preclinical data demonstrating that Prime Editing-mediated removal of pathological repeats in vitro results in correction of hypermethylation at the FXN gene, restoring genetic function back to wild-type levels.
  • Off-target Safety Data: Prime Medicine is progressing a comprehensive suite of assays to evaluate the potential off-target activity of its Prime Editors.
  • Prime Medicine is using PCSK9 as a model system for developing its modular LNP delivery platform to the liver.
  • Prime Medicine expects the following activities and next steps to drive the Prime Editing platform forward:
    Nominate first development candidate for CGD in 1Q 2023.

CGTN: TCM continues to play significant role in treating COVID-19

Retrieved on: 
Wednesday, January 11, 2023

BEIJING, Jan. 11, 2023 /PRNewswire/ -- Traditional Chinese Medicine (TCM) has been playing an important role in China's fight against COVID-19.

Key Points: 
  • BEIJING, Jan. 11, 2023 /PRNewswire/ -- Traditional Chinese Medicine (TCM) has been playing an important role in China's fight against COVID-19.
  • The new protocol introduces targeted TCM treatments for severe cases, and puts forward relatively complete therapeutic TCM solutions for children.
  • The country has also developed a unique plan to treat COVID-19 epidemic by combining the use of both TCM and Western medicine for severe and critical patients.
  • "Patients can choose proper TCM for home treatment to reduce the overloading risk and pressure on medical institutions and resources."

CGTN: TCM continues to play significant role in treating COVID-19

Retrieved on: 
Wednesday, January 11, 2023

BEIJING, Jan. 11, 2023 /PRNewswire/ -- Traditional Chinese Medicine (TCM) has been playing an important role in China's fight against COVID-19.

Key Points: 
  • BEIJING, Jan. 11, 2023 /PRNewswire/ -- Traditional Chinese Medicine (TCM) has been playing an important role in China's fight against COVID-19.
  • The new protocol introduces targeted TCM treatments for severe cases, and puts forward relatively complete therapeutic TCM solutions for children.
  • The country has also developed a unique plan to treat COVID-19 epidemic by combining the use of both TCM and Western medicine for severe and critical patients.
  • "Patients can choose proper TCM for home treatment to reduce the overloading risk and pressure on medical institutions and resources."

Visby Medical™ Receives FDA Emergency Use Authorization for Respiratory Health Test for use in CLIA waived settings

Retrieved on: 
Tuesday, January 3, 2023

SAN JOSE, Calif., Jan. 3, 2023 /PRNewswire/ -- Visby Medical™ announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for its Respiratory Health point of care test.

Key Points: 
  • SAN JOSE, Calif., Jan. 3, 2023 /PRNewswire/ -- Visby Medical™ announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for its Respiratory Health point of care test.
  • The Visby Medical Respiratory Health Test is a fast, polymerase chain reaction (PCR) device that detects and differentiates between upper respiratory infections caused by Influenza (Flu) A & B, and SARS-CoV-2 (COVID-19).
  • Visby Medical has received EUA from the FDA for its Respiratory Health point of care test.
  • He further added, "Use of the Visby Respiratory Health Test at the point of care in urgent care clinics and emergency rooms will transform how patients with respiratory symptoms are diagnosed and treated."

Wellbeing Subsidiary KGK Science Announces Successful Results of UP446, a Nutraceutical Ingredient, in Positive Immune Defense Response

Retrieved on: 
Tuesday, December 6, 2022

The randomized, triple-blind, placebo-controlled clinical trial involving supplementation with bioflavonoid composition UP446 provides evidence for a robust, healthy immune response in adults following influenza vaccination.

Key Points: 
  • The randomized, triple-blind, placebo-controlled clinical trial involving supplementation with bioflavonoid composition UP446 provides evidence for a robust, healthy immune response in adults following influenza vaccination.
  • Healthy adult participants, who had not yet received their influenza vaccine, between 40-80 years of age were randomized to either UP446 or placebo for 56 days.
  • Influenza-specific IgG antibodies significantly increased with UP446 supplementation from Day 28 to 56 and from baseline at Day 56.
  • Using a vaccine model provided a unique and novel way to examine the effect of UP446 supplementation on the immune response.

Global Bacteriophage Therapy Market Report 2022: Looming Threat of Antimicrobial Resistance Drives Research & Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The "Bacteriophage Therapy Market: Distribution by Therapeutic Area, Route of Administration, and Geography: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bacteriophage Therapy Market: Distribution by Therapeutic Area, Route of Administration, and Geography: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • Given the afore-mentioned advantages of bacteriophage therapy and promising insights from the ongoing research, various clinical trials have been registered for the clinical evaluation of bacteriophage therapies.
  • In fact, with the widespread participation of stakeholders in the research and development of bacteriophage therapy, clinical studies evaluating bacteriophage therapy have increased at a growth rate of more than 30% over the last few years.
  • With increasing R&D efforts, promising clinical data, and financial support from investors, we anticipate the bacteriophage therapy market to witness notable growth in the mid to long term.